文献速递神经肿瘤

Withaferin A与肿瘤治疗电场协同抑制胶质瘤细胞增殖

Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields.
PubMed 文献 · J Neurooncol · 2017-07-05

本研究以人胶质母细胞瘤细胞系(GBM2、GBM39、U87-MG)及人乳腺腺癌细胞系(MDA-MB-231)为对象,评估Withaferin A与肿瘤治疗电场(TTFields)联合应用的抗增殖效果。TTFields(4 V/cm)显著抑制四种癌细胞系生长(每个时间点n=3次实验,每样本四次测量,p<0.02至少;双因素方差分析,对照 vs 处理)。Withaferin A(10-100 nM)与TTFields联合对胶质瘤细胞的生长抑制程度超过单用Withaferin A或单用TTFields,两者交互作用呈协同性(p<0.01,n=3次实验),经生物发光成像和血细胞计数仪测量双重验证。

要点

  • TTFields(4 V/cm)显著抑制四种癌细胞系生长(p<0.02至少)。
  • Withaferin A(10-100 nM)联合TTFields对胶质瘤细胞的抑制超过单药或单用TTFields。
  • Withaferin A与TTFields对胶质瘤细胞的交互作用呈协同性(p<0.01,n=3次实验)。

核心结论

  • Withaferin A与TTFields联合可能优于任一单独治疗,且对胶质瘤细胞呈协同抑制增殖作用。

研究设计与样本

  • 研究使用人胶质母细胞瘤细胞系(GBM2、GBM39、U87-MG)和人乳腺腺癌细胞系(MDA-MB-231),胶质瘤细胞系经基因工程表达萤火虫荧光素酶;增殖潜能通过生物发光成像或血细胞计数仪细胞计数评估。

主要发现

  • TTFields(4 V/cm)显著抑制四种受试癌细胞系的生长(每个时间点n=3次实验,每样本四次测量,p<0.02至少;双因素方差分析,对照 vs 处理)。
  • Withaferin A(10-100 nM)联合TTFields对胶质瘤细胞的生长抑制程度超过单用Withaferin A或单用TTFields。
  • Withaferin A与TTFields对胶质瘤细胞的交互作用呈协同性(p<0.01,n=3次实验)。
  • 上述发现经生物发光和血细胞计数仪测量双重验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma (GBM) is the most aggressive and lethal form of brain cancer. Standard therapies are non-specific and often of limited effectiveness; thus, efforts are underway to uncover novel, unorthodox therapies against GBM. In previous studies, we investigated Withaferin A, a steroidal lactone from Ayurvedic medicine that inhibits proliferation in cancers including GBM. Another novel approach, tumor treating fields (TTFields), is thought to disrupt mitotic spindle formation and stymie proliferation of actively dividing cells. We hypothesized that combining TTFields with Withaferin A would synergistically inhibit proliferation in glioblastoma. Human glioblastoma cells (GBM2, GBM39, U87-MG) and human breast adenocarcinoma cells (MDA-MB-231) were isolated from primary tumors. The glioma cell lines were genetically engineered to express firefly luciferase. Proliferative potential was assessed either by bioluminescence imaging or cell counting via hemocytometer. TTFields (4 V/cm) significantly inhibited growth of the four cancer cell lines tested (n = 3 experiments per time point, four measurements per sample, p < 0.02 at least; 2-way ANOVA, control vs. treatment). The combination of Withaferin A (10-100 nM) with TTFields significantly inhibited the growth of the glioma cells to a degree beyond that of Withaferin A or TTFields alone. The interaction of the Withaferin A and TTFields on glioma cells was found to be synergistic in nature (p < 0.01, n = 3 experiments). These findings were validated by both bioluminescence and hemocytometric measurements. The combination of Withaferin A with TTFields represents a novel approach to treat GBM in a manner that is likely better than either treatment alone and that is synergistic.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Chang E, Pohling C, Beygui N, et al. Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields. J Neurooncol. 2017. PMID: 28681243. doi:10.1007/s11060-017-2534-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。